[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569458":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":38,"responsibleParty":56,"collaborators":12,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":12,"enrollmentInfo":68,"targetDuration":12,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":81,"whyStopped":12,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with regular follow-up for their GHD (treated with rhGH or not)","NO_INTERVENTION","Patients with regular follow-up for their GHD (treated with rhGH or not) in a adult endocrinology department including a clinical examination and endocrine blood work-up at least once a year",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Patients who are lost to follow-up or not regularly followed for their GHD","ACTIVE_COMPARATOR","Patients who are lost to follow-up or not regularly followed for their GHD (or only followed by their GP with no endocrine assessment)",[18],"Other: Biological Sample",[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":12},"Biological Sample","Clinical examination and blood test. The clinical examination and blood test are considered standard-of-care as they could be performed annually or bi-annually as part of an adult GHD follow-up. Subsequently, the data will be collected directly from the patient's chosen physician.",[14],[25],{"name":26,"affiliation":5,"role":27},"Philippe Lysy, MD, PhD","PRINCIPAL_INVESTIGATOR",[29,34],{"name":26,"role":30,"phone":31,"phoneExt":32,"email":33},"CONTACT","02 7641370","+32","philippe.lysy@saintluc.uclouvain.be",{"name":35,"role":30,"phone":36,"phoneExt":32,"email":37},"Laure Boutsen, MD","02 7641933","laure.boutsen@saintluc.uclouvain.be",[39],{"facility":40,"status":12,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Cliniques Universitaires Saint-Luc","Brussels","Woluwe-saint-lambert","1200","Belgium","BE",{"type":47,"coordinates":48},"Point",[49,50],4.34878,50.85045,{"lat":50,"lon":49},[53],{"name":54,"role":30,"phone":55,"phoneExt":12,"email":33},"Philippe Lysy, Pr","+3227641370",{"type":57,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100569458","belux-children-outcome-during-adulthood-with-ghd-100569458",false,"NCT06694506","BELux Children OutcoME During A(@)Dulthood With GHD","BELux Children OutcoME During A(@)Dulthood With Growth Hormone Deficiency","BELCOME@GHD","Inclusion Criteria:\n\n* Age \\> or = 18 years\n* Diagnosed with child-hood onset growth hormone deficiency (CO-GHD) (no exclusion criteria: isolated or multiple GHD, idiopathic or organic, severe or partial)\n* Registered in the BELGROW registry (informed consent at the time of inclusion in registry)\n* Stopped treatment with rhGH for growth after 2011\n* Persistent GHD at the end of growth\n\nExclusion Criteria:\n\n* No exclusion criteria","ALL","18 Years",{"count":69,"type":70},200,"ESTIMATED","INTERVENTIONAL",[73],"NA","Our objective is to evaluate the outcome in adulthood of Belgian and Luxembourgish patients treated with rhGH during childhood for CO-GHD. The primary goal is to determine the proportion of adult CO-GHD patients who continue to receive regular medical follow-up and those still undergoing rhGH therapy using a questionnaire. Secondary objectives include assessing the regularity of follow-up and compliance with treatment in adulthood, evaluating possible comorbidities, health issues, lifestyle, living environment, and quality of life. Additionally, we aim to assess the metabolic profile in adulthood, particularly focusing on BMI, glycemic, and lipid data, for patients who consent to share their current clinical and biological data. Data will be described according to treatment adherence and CO-GHD etiology\u002Fphenotypes (e.g., idiopathic vs. organic GHD, isolated vs. combined GHD, partial vs. severe GHD).",[76,77],"Growth Hormone Deficiency","Adult Growth Hormone Deficiency",[79,80],"Growth Hormone","Adult","NOT_YET_RECRUITING","2024-11-15",{"date":84,"type":85},"2024-11-19","ACTUAL",{"date":87,"type":70},"2024-12-15",{"date":89,"type":70},"2029-08-01",{"name":5,"class":6},1]